NEWS
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio (Nasdaq: ETNB) announced that new analyses from the Phase 2b ENLIVEN trial of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented at the 75th Annual AASLD The Liver Meeting® 2024. The presentations include four poster sessions focusing on:
Biomarker response in high-risk MASH patients
Reduction in progression to cirrhosis
Machine learning integration for biomarker assessments
Diagnostic potential of FAST and AGILE3+ scores for F2/F3 fibrosis
The presentations will take place on November 15-16, 2024, in San Diego, California, featuring research from prominent medical professionals in the field of liver health.
Biomarker response in high-risk MASH patients
Reduction in progression to cirrhosis
Machine learning integration for biomarker assessments
Diagnostic potential of FAST and AGILE3+ scores for F2/F3 fibrosis
The presentations will take place on November 15-16, 2024, in San Diego, California, featuring research from prominent medical professionals in the field of liver health.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2625Followers
107Following
28KVisitors
Follow